ReviewCurrent opinion in pulmonary medicine2014
Morbidity and mortality in sarcoidosis.
Review in Current opinion in pulmonary medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 120 citations in OpenAlex.
- Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomised, double-blinded, multicentre, phase 2 study.The European respiratory journal · 2026Trial
- Morphological computed tomography phenotypes in pulmonary sarcoidosis at diagnosis: splitting and lumping based on predictors of clinical progression.ERJ open research · 2026Article
- Treatable traits approach for personalised management of sarcoidosis.BMJ open respiratory research · 2026Review
- Autoimmune Diseases and the Vestibular and Oculomotor System: Clinical Presentation, Diagnosis, and Treatment.Journal of eye movement research · 2026Review
- The Diagnostic Course of Sarcoidosis: A Population-Based Study Highlighting Risk Factors for a Delay in Diagnosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Electrocardiographic abnormalities attributable to infiltrative cardiomyopathies: review and prevalence in patients with congestive heart failure.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Article
- Enlarged, activated alveolar macrophages as quantitative surrogates of disease activity in pulmonary sarcoidosis.Frontiers in medicine · 2026Article
- Burden and impact of pulmonary embolism in young adults hospitalized with sarcoidosis: Underreported data from nationwide analysis (2016-2020).Lung India : official organ of Indian Chest Society · 2026Article
- Article
- Neuropsychiatric manifestations of sarcoidosis.Annals of medicine · 2025Review
- Exploring gender and ethnic disparities in sarcoidosis: insights from the British Thoracic Society UK Interstitial Lung Disease Registry.BMJ open respiratory research · 2025Article
- Sarcoidosis in the Genomic Era: From Genetic Drivers to Tailored Therapies.Current allergy and asthma reports · 2025Review
- Article
- Global epidemiology and burden of interstitial lung disease.The Lancet. Respiratory medicine · 2025Review
- Delays in Referral to Multidisciplinary Care for Black Individuals With Sarcoidosis.CHEST pulmonary · 2025Article
- Incidence, prevalence, and mortality of sarcoidosis in England: a population-based study.The Lancet regional health. Europe · 2025Article
- Fibrotic Pulmonary Sarcoidosis-From Pathogenesis to Management.Journal of clinical medicine · 2025Review
- Phenotyping sarcoidosis: a single institution retrospective analysis.Frontiers in medicine · 2025Article
- Rheumatologic Perspectives on Sarcoidosis: Predicting Sarcoidosis-Associated Arthritis Through Comprehensive Clinical and Laboratory Assessment.Journal of clinical medicine · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
purpose of reviewChronic sarcoidosis is a complex disease with numerous comorbid conditions and can be fatal in some cases. Recognizing causes of morbidity and mortality is important to effectively select treatments, manage symptoms and improve outcomes. The purpose of this review is to examine emerging knowledge on morbidity and mortality in sarcoidosis. RECENT
findingsApproximately 1-5% of patients with sarcoidosis die from complications of sarcoidosis. Recent population studies indicate that mortality may be increasing over the past decade. The reasons behind these trends are unclear, but could include increasing incidence, detection rates, severity of disease or age of the population. Morbidity of sarcoidosis is reflected by a trend of increased hospitalizations over recent years and increased use of healthcare resources. Morbidity can be caused by organ damage from granulomatous inflammation, treatment complications and psychosocial effects of the disease. Recent studies are focused on morbidity related to cardiopulmonary complications, bone health and ageing within the sarcoidosis population. Last, sarcoidosis is associated with autoimmune diseases, pulmonary embolism and malignancy; however, the underlying mechanisms linking diseases continue to be debated. SUMMARY: Morbidity in sarcoidosis is significant and multifactorial. Mortality is infrequent, but may be increasing over the years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.